Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) is expected to release its Q1 25/26 earnings data before the market opens on Friday, July 25th. Analysts expect Dr. Reddy's Laboratories to post earnings of $0.19 per share and revenue of $88.27 billion for the quarter.
Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.20 by $0.02. Dr. Reddy's Laboratories had a net margin of 17.38% and a return on equity of 17.98%. The company had revenue of $996.17 million during the quarter, compared to analyst estimates of $83.70 billion. On average, analysts expect Dr. Reddy's Laboratories to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Dr. Reddy's Laboratories Price Performance
Shares of NYSE RDY opened at $14.70 on Friday. Dr. Reddy's Laboratories has a twelve month low of $12.26 and a twelve month high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.37 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $12.28 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 5.18 and a beta of 0.33. The firm has a 50-day moving average of $14.89 and a two-hundred day moving average of $14.14.
Wall Street Analysts Forecast Growth
A number of analysts have commented on RDY shares. Hsbc Global Res raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. HSBC raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating and upped their price objective for the company from $14.44 to $16.90 in a research note on Thursday, June 5th. Finally, Wall Street Zen raised shares of Dr. Reddy's Laboratories from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $16.95.
Check Out Our Latest Stock Analysis on Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Company Profile
(
Get Free Report)
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dr. Reddy's Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Reddy's Laboratories wasn't on the list.
While Dr. Reddy's Laboratories currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
